Last reviewed · How we verify
nicardipine intravenous
Nicardipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation and reducing blood pressure.
Nicardipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation and reducing blood pressure. Used for Acute hypertension management, Hypertensive emergency, Perioperative hypertension.
At a glance
| Generic name | nicardipine intravenous |
|---|---|
| Also known as | Nicardipine hydrochloride |
| Sponsor | Haseki Training and Research Hospital |
| Drug class | Dihydropyridine calcium channel blocker |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nicardipine selectively blocks L-type calcium channels in vascular smooth muscle, preventing calcium-dependent contraction. This results in peripheral vasodilation and reduced systemic vascular resistance, leading to decreased blood pressure. The intravenous formulation allows for rapid onset and titration, making it useful for acute hypertensive episodes.
Approved indications
- Acute hypertension management
- Hypertensive emergency
- Perioperative hypertension
Common side effects
- Headache
- Flushing
- Tachycardia
- Dizziness
- Nausea
- Injection site reactions
Key clinical trials
- A Comparison of Nicardipine and Labetalol for Blood Pressure Control in Intensive Care Patients After Hemorrhagic Stroke Brain Surgery (NA)
- Nicardipine vs. Labetalol (PHASE4)
- Anesthesia Management in Endovascular Therapy for Ischemic Stroke - 2 (NA)
- Effect of Individualized Versus Standard Bp Management During MT for Anterior Ischemic Stroke (NA)
- Clinical Relevance of Nicardipine Induced Hypoxemia in the Intensive Care Unit
- Blood Pressure After Endovascular Stroke Therapy-II (PHASE2)
- Pupillary Reflex Measurement to Guide Intraoperative Analgesia During Laparoscopic Surgery (NA)
- Nicardipine and Labetalol Effects on Cerebral Hemodynamics in Preeclampsia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nicardipine intravenous CI brief — competitive landscape report
- nicardipine intravenous updates RSS · CI watch RSS
- Haseki Training and Research Hospital portfolio CI